HRS9432 / Jiangsu Hengrui Pharma - LARVOL DELTA

A Trial of Intravenous HRS9432 in the Treatment of Subjects With Candidemia and/or Invasive Candidiasis (clinicaltrials.gov) - P2 | N=61 | Completed | Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. | Recruiting ➔ Completed | N=40 ➔ 61 | Trial completion date: Jun 2026 ➔ Nov 2025 | Trial primary completion date: Jun 2026 ➔ Nov 2025

Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Candidiasis

Safety, tolerability, and pharmacokinetics of HRS9432(A) injection in healthy Chinese subjects: a phase-I randomized, double-blind, dose escalation, placebo-controlled study. (PubMed, Antimicrob Agents Chemother) - "The pharmacokinetic exhibited essentially linear characteristics in the body, supporting a weekly dosing frequency for clinical applications and providing additional options for the treatment or prevention of invasive fungal infections. This study is registered with the International Clinical Trials Registry Platform as ChiCTR2300073525."

Clinical • Journal • P1 data • PK/PD data • Candidiasis • Infectious Disease

A Trial of Intravenous HRS9432 in the Treatment of Subjects With Candidemia and/or Invasive Candidiasis (clinicaltrials.gov) - P2 | N=40 | Recruiting | Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting | Initiation date: Jan 2024 ➔ Apr 2024

Enrollment open • Trial initiation date • Candidiasis

A Trial of Intravenous HRS9432 in the Treatment of Subjects With Candidemia and/or Invasive Candidiasis (clinicaltrials.gov) - P2 | N=40 | Not yet recruiting | Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.

New P2 trial • Candidiasis